Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

3.1K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.1K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

602
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
602
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

515
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
515

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Brachial Artery Pulse Pressure: Perspectives on Pathophysiology in Women Without Obstructive Coronary Disease.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation.

Journal of the American Society of Nephrology : JASN·2026
Same author

Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Enabling a Renin-Angiotensin System Inhibitor and/or a Mineralocorticoid Receptor Antagonist in Patients With Heart Failure and/or Chronic Kidney Disease: Unintended Consequences of Increased Sodium Exposure.

JACC. Heart failure·2026
Same author

Impact of older donor age in kidney transplants in a biopsy-based observational study.

JCI insight·2026
Same author

Corrigendum to "Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants" [American Journal of Transplantation Volume 26, Issue 1, January 2026, Pages 117-130].

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026

相关实验视频

Updated: Apr 13, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.6K

2025年脏保护选择:2025年脏保护选择:2025年脏保护选择:2025年脏保护选择:2025年脏保护选择:2025年脏保护选择:2025年脏保护选项:2025年脏保护选项:2025年脏保护选项:2025年脏保护选项:2025年脏保

Matthew R Weir1

  • 1Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.

Seminars in nephrology
|March 3, 2026
PubMed
概括

ангиотензин转化酶抑制剂减缓病的进展,但由于副作用的担忧,许多临床医生避免使用它们. 新的疗法可能会在实践中掩盖这些既定药物.

关键词:
保护脏 保护脏血清过高的高卡利米亚.新的治疗方法氨酸 - ангиотензин 系统的抑制抑制.

更多相关视频

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

相关实验视频

Last Updated: Apr 13, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.6K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.8K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

科学领域:

  • 腎臟病學 (nephrology) 是一種醫學.
  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 抗胰岛素转化酶 (ACE) 抑制剂,这些抑制剂修改了宁-胰岛素系统 (RAS),已经在减缓病进展方面表现出40多年的好处.
  • 尽管在减少心脏和脏事件方面已被证明是有效的,但RAS抑制剂的持续临床使用是次优的.
  • 对血清肌素升高和高血的担忧限制了这些疗法的广泛采用.

研究的目的:

  • 评估目前的作用和未来的前景,在慢性病 (CKD) 和心血管事件的多式管理中抑制-血管酶系统 (RAS).
  • 为了解决围绕RAS抑制剂使用的临床惯性,尽管已确立的好处.

主要方法:

  • 对临床试验数据和关于RAS抑制剂和较新的心保护疗法的已建立文献的审查.
  • 对影响临床实践模式的因素分析,涉及抗高血压和心保护药物.

主要成果:

  • 拉斯抑制剂在减缓CKD进展和减少心脏和脏事件方面是有效的.
  • 临床医生犹的原因是担心高血和血清肌素增加.
  • 具有潜在副作用较少的新疗法正在作为替代品或辅助产品出现.

结论:

  • 在当代心脏内保护策略中RAS抑制的最佳作用需要重新评估.
  • 随着多式疗法的发展,RAS抑制的基本状态可能会受到挑战.
  • 需要进一步的研究和临床指导,以优化RAS抑制剂与新药一起使用.